Efficacy and Safety Study of Magnesium Isoglycyrrhizinate Injection in Subjects With Acute Drug-induced Liver Injury


The purpose of this study is to investigate the safety, effective dosage and treatment of Magnesium Isolycyrrhizinate Injection to cure the acute drug-induced liver injury compared with the Tiopronin Injection.

Full Title of Study: “A Multi-center, Randomized, Double-blind, Active Control Phase II Study to Investigate Multiple Dosage and Treatments of Magnesium Isoglycyrrhizinate Injection to Cure the Acute Drug-induced Liver Injury”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: December 2008

Detailed Description

The pharmacology research shows that Magnesium Isoglycyrrhizinate could significantly decrease the elevation of ALT and AST coursed by carbon tetrachloride, D-galactosamine and Thioacetamide. It could also significantly reduce the injury on the liver coursed by D-galacosamine and immunologic factors. Magnesium Isoglycyrrhizinate with strong anti-inflammatory effect could protect the liver cell and improve the liver function.


  • Drug: Magnesium Isoglycyrrhizinate Injection 100mg OD
    • Magnesium Isoglycyrrhizinate Injection 100mg OD
  • Drug: Magnesium Isoglycyrrhizinate Injection 200mg OD
    • Magnesium Isoglycyrrhizinate Injection 200mg OD for 4 weeks
  • Drug: Tiopronin Injection
    • Tiopronin Injection 200mg OD

Arms, Groups and Cohorts

  • Experimental: arm 1
    • lower dose: Magnesium Isoglycyrrhizinate injection 100mg OD for 4 weeks
  • Experimental: arm 2
    • higher dose:Magnesium Isoglycyrrhizinate injection 200mg OD for 4 weeks.
  • Active Comparator: Tiopronin Injection
    • Tiopronin Injection 200mg OD for 4 weeks

Clinical Trial Outcome Measures

Primary Measures

  • Rate of ALT normalization at week 4 of treatment
    • Time Frame: 4 weeks

Secondary Measures

  • rates of ALT normalization at weeks 1, 2, and 3 of treatment
    • Time Frame: 3 weeks
  • change of ALT at weeks 1, 2, 3 and 4 of treatment;
    • Time Frame: 4 weeks
  • change of AST at weeks 1, 2, 3 and 4 of treatment.
    • Time Frame: 4 weeks

Participating in This Clinical Trial

Inclusion Criteria

  • RACUM ≥6
  • ALTs ≥2ULN, but TBiL is ≤ 3 ULN.It may be associated with AST or ALP or TBiL exceed the upper limit of normal
  • Liver biochemical abnormalities duration of no more than three months
  • Patients need to fully understand and sign the inform consent form.

Exclusion Criteria

  • The liver injury is caused by other diseases, such as virus hepatitis, alcohol and non-alcohol fatty liver disease or the autoimmune liver disease.
  • The patients with the acute hepatic failure or hepatic decompensation, such as hepatic encephalopathy, ascites, albumin is ≤ 35g/L, prothrombin time is elongated more than 2 seconds compared to its normal range.
  • The value of the TBiL is > 3ULN.
  • The value of serum creatinine is > 1.5ULN.
  • Patients who have severe organic diseases on heart, lungs, brain, kidney and gastrointestinal tract.
  • Patients who are taking the drugs that might interfere the trial.
  • Patients who are allergic or intolerant to the study drug.
  • Patients who are not able to express the chief complaint, for example, the patients with psychosis and severe neurosis.
  • Patients who are compliant with protocol.
  • Women who are pregnant, breast-feeding or with childbearing potential.
  • Patients who have attended other clinical trials within 3 months.
  • Not appropriate to be included after assessing by the investigators.

ULN=Upper Limited Normal

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 70 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Minde Zeng, MD, Principal Investigator, RenJi Hospital


Maria VA, Victorino RM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology. 1997 Sep;26(3):664-9.

Watkins PB, Seeff LB. Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology. 2006 Mar;43(3):618-31.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.